Opalite Health
AI speech-to-speech medical interpreter for 150+ languages with EHR integration
Website: https://opalitehealth.com/
Cover Block
PUBLIC
| Company | Opalite Health |
| Tagline | AI speech-to-speech medical interpreter for 150+ languages with EHR integration |
| Headquarters | San Francisco, United States |
| Founded | 2025 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Undisclosed |
Links
PUBLIC
- Website: https://opalitehealth.com/
- LinkedIn: https://www.linkedin.com/company/opalite-health
Executive Summary
PUBLIC
Opalite Health is a Y Combinator-backed startup applying real-time AI speech-to-speech interpretation to a persistent and costly problem in healthcare: the language barrier between clinicians and patients. The company's early momentum, driven by a physician-founder with a personal connection to the problem, merits investor attention for its potential to automate a critical, non-discretionary service line within provider budgets.
The company was founded in 2025 by Cathleen Kuo, a physician and AI researcher, after she witnessed her immigrant parents struggle within the U.S. healthcare system [Y Combinator LinkedIn, 2026]. Its core product translates clinician-patient conversations across 150+ languages directly within clinical workflows, integrating with electronic health records and generating automated documentation [Opalite Health, 2026]. The primary wedge is economic, claiming to replace traditional interpreter services with software that is "over 50% cheaper" while being faster and embedded in the care experience [Y Combinator LinkedIn, 2026].
Cathleen Kuo brings a relevant background in AI healthcare research, with a reported 150+ publications and prior experience as a co-founder of MedDx, an AI prognostic platform [F6S, 2026]. Technical leadership is provided by co-founder and CTO Alex Mehregan, though his specific prior experience is not detailed in public sources [Crunchbase, 2026]. The company is currently in the seed stage, having completed the Y Combinator Winter 2026 batch, but the specific amount of capital raised and any other investors remain undisclosed [F6S, 2026].
Over the next 12-18 months, the key watchpoints will be the validation of its quality and cost claims at scale, the signing of named enterprise health system customers, and the expansion of its tiny team to support a complex enterprise sales and implementation motion. Early, unverified traction signals include translating over 10,000 minutes per month across more than 10 U.S. states [Y Combinator LinkedIn, 2026] [Hiretop, 2026].
Data Accuracy: YELLOW -- Core product claims are confirmed by the company website. Foundational team and traction details are sourced from secondary platforms (F6S, Hiretop) and a Y Combinator post, but lack independent verification from major news outlets.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
Company Overview
PUBLIC
Opalite Health was founded in 2025 by CEO Cathleen Kuo and CTO Alex Mehregan, emerging from Kuo's personal experience watching her immigrant parents navigate the U.S. healthcare system with a language barrier [Y Combinator, 2026]. The company is headquartered in San Francisco, California, and operates as part of the broader Bay Area startup ecosystem, with one secondary source also noting a presence in Palo Alto [F6S, 2026] [Hiretop, 2026]. Its primary legal entity is not detailed in public filings or on its website.
Key milestones follow a compressed timeline typical of Y Combinator-backed ventures. The company was accepted into the Y Combinator Winter 2026 batch, a foundational event that provided initial capital and network access [F6S, 2026]. Shortly after, Opalite began deploying its product, with the company claiming it is "already live across hospitals and clinics, translating 10,000+ minutes per month" and in active use across more than ten U.S. states by 2026 [Y Combinator, 2026] [Hiretop, 2026]. These early deployment claims, while not yet accompanied by named customer logos, represent the core traction narrative for the seed-stage firm.
Data Accuracy: YELLOW -- Founding story and YC affiliation confirmed by Y Combinator; headquarters and early traction claims are single-source or partially corroborated.
Product and Technology
MIXED The core proposition is an AI interpreter that sits directly inside a clinical workflow, aiming to replace scheduled human services with on-demand software. According to the company's website, the product delivers real-time, speech-to-speech interpretation across more than 150 languages, integrated with electronic health record systems and built on a HIPAA-compliant infrastructure [Opalite Health, 2026]. This positions it not as a standalone app but as an embedded layer within the tools clinicians already use.
Beyond translation, the system generates automated clinical documentation from the interpreted conversation, a feature noted in secondary profiles [Extruct AI, 2026]. The company claims its software is "over 50% cheaper" than traditional interpretation services, framing the economic wedge as cost reduction paired with immediacy [Y Combinator, 2026]. Public traction claims, such as translating over 10,000 minutes per month across hospitals and clinics, suggest the product is beyond a prototype and in active, albeit early, deployment [Y Combinator, 2026].
Technical details on the underlying model architecture, data sources for medical terminology, or specific EHR integration partners are not publicly disclosed. The product's differentiation appears to hinge on workflow integration and cost, rather than on a novel, proprietary AI model claimed to be superior to all others.
Data Accuracy: YELLOW -- Core product claims are sourced from the company website and Y Combinator; traction and documentation features are reported by secondary profiles.
Market Research
PUBLIC The market for language services in U.S. healthcare is a persistent, multi-billion dollar operational cost center, now facing pressure from both rising patient diversity and tightening hospital budgets, creating a clear wedge for cost-saving technology.
Third-party sizing for the specific AI medical interpretation segment is not yet available. The most relevant analogous market is the broader healthcare language services industry. According to a 2022 report from Grand View Research, the global healthcare interpreting services market was valued at $5.6 billion and was projected to grow at a compound annual rate of 5.5% through 2030 [Grand View Research, 2022]. The U.S. represents the largest regional segment of this market, driven by federal mandates. The demand is underpinned by Title VI of the Civil Rights Act and Section 1557 of the Affordable Care Act, which require federally funded healthcare providers to offer language assistance services, creating a non-discretionary compliance spend [Hiretop, 2026].
Key demand drivers extend beyond compliance. The U.S. population with limited English proficiency continues to grow, increasing the volume of clinical encounters requiring interpretation. Simultaneously, healthcare systems face significant financial strain, making the high cost of traditional human interpreter services,often billed by the minute with minimum call durations and scheduling overhead,a target for operational efficiency. The shift towards telehealth and decentralized care models further complicates the logistics of deploying human interpreters, creating a need for always-available, embedded solutions.
Regulatory and macro forces are shaping the landscape. While mandates create a stable demand floor, they also impose quality and documentation requirements that any solution must meet. The push for value-based care and risk-sharing payment models incentivizes providers to improve patient outcomes and reduce readmissions, where clear communication is a critical factor. However, the market is also adjacent to and competes with substitute solutions, including in-house interpreter staff, large traditional language service providers (LSPs), and basic telephonic interpretation services. The key differentiator for a new entrant is not creating demand but capturing existing spend by demonstrating superior cost, convenience, and integration.
| Metric | Value |
|---|---|
| Global Healthcare Interpreting Services (2022) | 5.6 $B |
| Projected Annual Growth Rate (2022-2030) | 5.5 % |
The cited market size, while for the broader service category, establishes the substantial baseline expenditure that technology solutions aim to displace. The single-digit growth rate suggests a mature, compliance-driven market where share capture, rather than market expansion, is the primary growth lever for a new vendor.
Data Accuracy: YELLOW -- Market sizing is from an analogous, dated third-party report; demand driver and regulatory context are cited from secondary analysis.
Competitive Landscape
MIXED Opalite Health enters a fragmented market for language services in healthcare, positioned as a software-first challenger to traditional human interpreter networks and emerging AI point solutions.
The competitive analysis proceeds based on the known market structure.
The competitive map splits into three distinct segments. The incumbent layer consists of large, established human interpretation services like LanguageLine Solutions and AMN Healthcare's Stratus Video, which dominate hospital contracts through long-standing relationships and compliance certifications. These services are the primary target for replacement, as Opalite claims to be "over 50% cheaper" and faster [Y Combinator, 2026]. The second segment includes AI-native challengers, such as startups developing specialized medical translation models, though none are named in the available sources. The third comprises adjacent substitutes: telehealth platforms with built-in interpretation (e.g., Teladoc, Amwell) and EHR vendors that may eventually embed similar functionality natively, representing a potential channel conflict or partnership opportunity.
Opalite's current edge appears to rest on two pillars: workflow integration and founder credibility. The company's emphasis on deep "EHR integration" and "automated clinical documentation" aims to embed the tool directly into clinician workflows, a stickiness factor that pure audio-translation APIs lack [Extruct AI, 2026] [Opalite Health website, 2026]. Furthermore, CEO Cathleen Kuo's background as a physician and AI researcher provides a credential that may accelerate trust-building with early-adopter health systems [F6S, 2026]. However, both edges are perishable. Integration depth can be replicated by well-funded incumbents or EHR platforms themselves, and founder credibility, while a powerful wedge, does not constitute a long-term technical moat.
The company's most significant exposure lies in its nascent scale and unproven quality at enterprise level. While it claims use "across more than 10 states" [Hiretop, 2026], the lack of named customer logos leaves it vulnerable to competitors with deeper enterprise sales footprints and validated reference accounts. Furthermore, the claim of translation quality "superior to that of certified human medical interpreters" remains uncorroborated by published benchmarks and could be a key point of attack from incumbents who emphasize human nuance in high-stakes clinical conversations [Hiretop, 2026].
A plausible 18-month scenario hinges on execution speed and partnership formation. The winner in this segment will likely be the company that first secures a marquee, multi-facility health system contract and a formal integration partnership with a major EHR vendor. If Opalite can use its Y Combinator network to land such a partnership and begin generating proprietary, domain-specific training data from live deployments, it could establish a durable data advantage. Conversely, the loser will be any pure-play AI interpreter that fails to move beyond pilot programs and remains a feature rather than a platform, easily displaced by a bundled offering from a larger telehealth or EHR player.
Data Accuracy: YELLOW -- Competitive analysis is inferred from market structure; no named competitors are confirmed in public sources. Opalite's positioning claims are sourced from its website and Y Combinator materials.
Opportunity
PUBLIC If Opalite Health can successfully replace the traditional medical interpreter services market with its AI-driven software, the financial and operational prize is measured in billions of dollars of annual spend currently locked in a fragmented, high-latency, and labor-intensive industry.
The headline opportunity is to become the default, embedded layer for real-time language interpretation across the U.S. healthcare system. This outcome is reachable not merely because of a large market, but because the company's early positioning directly targets the core pain points of that market: cost and workflow friction. Y Combinator's public statement that the software is "over 50% cheaper" than traditional services [Y Combinator, 2026] provides a clear economic wedge, while claims of EHR integration and HIPAA compliance [Opalite Health, 2026] address the technical and regulatory barriers to adoption. The cited evidence of active use across more than 10 states [Hiretop, 2026] suggests the initial product is already navigating the complex patchwork of healthcare delivery, moving beyond a theoretical solution.
Growth scenarios, each named The path to scale hinges on specific, plausible expansion vectors beyond early adopters.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Enterprise Standardization | A major national health system or payer selects Opalite as its preferred vendor, rolling it out across hundreds of facilities. | A successful pilot within the "large healthcare enterprise" mentioned in secondary reporting [Hiretop, 2026] leads to a system-wide contract. | The product's design for EHR integration and workflow embedding [Extruct AI, 2026] aligns with enterprise procurement criteria for system-wide solutions. |
| Telehealth Platform Partnership | Opalite becomes the white-labeled interpretation layer for a leading telehealth provider, baked into millions of virtual visits annually. | A partnership with a telehealth platform seeking to reduce interpreter costs and improve visit efficiency for non-English speakers. | The company's focus includes "telehealth services" as a core buyer [Extruct AI, 2026], and the real-time, software-native model is a natural fit for virtual care. |
| Regulatory Mandate Expansion | New state or federal regulations strengthening language-access requirements create a compliance-driven adoption tailwind for certified AI tools. | Legislation akin to updates to Section 1557 of the Affordable Care Act, with specific provisions for "effective" communication. | The company's early emphasis on HIPAA compliance and audit trails [Extruct AI, 2026] positions it as a tool for demonstrating regulatory adherence, not just cost savings. |
What compounding looks like The core flywheel is data-driven quality improvement leading to lower costs and tighter workflow integration, which in turn drives more usage and data. Each minute of conversation translated generates data that can be used to refine medical-domain accuracy and dialect recognition, potentially improving quality claims over human interpreters [Hiretop, 2026]. As quality improves and costs remain structurally lower, health systems have a stronger rationale to replace entire interpreter service contracts, not just incremental minutes. This contract-level adoption creates distribution lock-in through deep EHR integration, making switching back to a traditional service or a competing AI product operationally disruptive. The early signal of this flywheel is the volume metric of "10,000+ minutes per month" [Y Combinator, 2026], which represents a recurring data stream that, if retained, forms the foundation of a proprietary dataset.
The size of the win A credible comparable for the potential outcome is the valuation of language services providers that serve healthcare. While no pure-play public AI medical interpreter exists, traditional language service companies like LanguageLine Solutions (owned by private equity) have been valued on revenue multiples reflecting stable, contract-based cash flows from a necessity service. If Opalite executes on the Enterprise Standardization scenario and captures a single-digit percentage of the estimated multi-billion dollar U.S. healthcare interpretation market, reaching, for instance, $100 million in annual recurring revenue, a premium SaaS multiple applied to that revenue would imply a valuation in the low billions. This is a scenario-specific outcome, not a forecast, but it frames the magnitude of the opportunity if the company can transition from a point solution to a standardized layer of care delivery infrastructure.
Data Accuracy: YELLOW -- Growth scenarios are extrapolated from cited product claims and early traction reports; specific catalysts (enterprise rollout) are referenced but not independently verified. Market size comparables are inferred from the broader industry, not a specific cited TAM.
Sources
PUBLIC
[Y Combinator, 2026] Opalite Health: Helping Healthcare Providers Speak Any Language | https://www.ycombinator.com/companies/opalite-health
[Opalite Health, 2026] Opalite Health | AI-Powered Medical Interpreter for Healthcare | https://opalitehealth.com/
[F6S, 2026] Opalite Health | https://www.f6s.com/company/opalite-health
[Hiretop, 2026] Opalite Health: Breaking Language Barriers in Healthcare | https://hiretop.com/blog5/opalite-health-language-barriers-healthcare/
[Extruct AI, 2026] Opalite Health Funding | Complete Analysis | Extruct AI | https://www.extruct.ai/hub/opalitehealth-com/
[Crunchbase, 2026] Alex Mehregan - Crunchbase Person Profile | https://www.crunchbase.com/person/alex-mehregan-41c4
[Grand View Research, 2022] Healthcare Interpreting Services Market Size Report, 2022-2030 | https://www.grandviewresearch.com/industry-analysis/healthcare-interpreting-services-market-report
[Y Combinator LinkedIn, 2026] Opalite Health (YC W26) is an AI medical interpreter | https://www.linkedin.com/posts/y-combinator_opalite-health-yc-w26-is-an-ai-medical-activity-7420208655117221888-YNEf
Articles about Opalite Health
- Opalite Health's AI Interpreter Replaces the Phone Booth in Ten States — The YC-backed startup is translating 10,000 minutes of clinical conversation monthly, betting software can cut interpreter costs in half.